img

Global Hypertension Medications Market Research Report 2024


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Hypertension Medications Market Research Report 2024

High blood pressure is a common condition that affects the body's arteries. It's also called hypertension. If you have high blood pressure, the force of the blood pushing against the artery walls is consistently too high. The heart has to work harder to pump blood. There are many different high blood pressure medications (antihypertensives) available, each with pros and cons.
According to Mr Accuracy reports’s new survey, global Hypertension Medications market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Hypertension Medications market research.
Key companies engaged in the Hypertension Medications industry include Pfizer, Novartis, AstraZeneca, Bayer, Sanofi, Boehringer Ingelheim, Merck, Lupin Pharmaceuticals and Huahai Pharmaceutical, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Hypertension Medications were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Hypertension Medications market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Hypertension Medications market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


Pfizer
Novartis
AstraZeneca
Bayer
Sanofi
Boehringer Ingelheim
Merck
Lupin Pharmaceuticals
Huahai Pharmaceutical
Jiangsu Jibeier Pharmaceutical
Tianjin Pharmaceutical Da Ren Tang Group
Chengdu Easton Biopharmaceuticals
Qingdao Huanghai Pharmaceutical
CR Double-Crane
Shanghai Shyndec Pharmaceutical
CSPC Pharmaceutical Group
Jiangsu Hengrui Medicine
Segment by Type
Calcium Channel Blockers
ACE Inhibitors
Angiotensin II Receptor Blockers
Beta Blockers
Compound Drugs
Diuretics
Others

Segment by Application


Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Hypertension Medications report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hypertension Medications Market Size Growth Rate by Type: 2024 VS 2022 VS 2034
1.2.2 Calcium Channel Blockers
1.2.3 ACE Inhibitors
1.2.4 Angiotensin II Receptor Blockers
1.2.5 Beta Blockers
1.2.6 Compound Drugs
1.2.7 Diuretics
1.2.8 Others
1.3 Market by Application
1.3.1 Global Hypertension Medications Market Growth by Application: 2024 VS 2022 VS 2034
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Hypertension Medications Market Perspective (2024-2034)
2.2 Hypertension Medications Growth Trends by Region
2.2.1 Global Hypertension Medications Market Size by Region: 2024 VS 2022 VS 2034
2.2.2 Hypertension Medications Historic Market Size by Region (2024-2024)
2.2.3 Hypertension Medications Forecasted Market Size by Region (2024-2034)
2.3 Hypertension Medications Market Dynamics
2.3.1 Hypertension Medications Industry Trends
2.3.2 Hypertension Medications Market Drivers
2.3.3 Hypertension Medications Market Challenges
2.3.4 Hypertension Medications Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hypertension Medications Players by Revenue
3.1.1 Global Top Hypertension Medications Players by Revenue (2024-2024)
3.1.2 Global Hypertension Medications Revenue Market Share by Players (2024-2024)
3.2 Global Hypertension Medications Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Hypertension Medications Revenue
3.4 Global Hypertension Medications Market Concentration Ratio
3.4.1 Global Hypertension Medications Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hypertension Medications Revenue in 2022
3.5 Hypertension Medications Key Players Head office and Area Served
3.6 Key Players Hypertension Medications Product Solution and Service
3.7 Date of Enter into Hypertension Medications Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Hypertension Medications Breakdown Data by Type
4.1 Global Hypertension Medications Historic Market Size by Type (2024-2024)
4.2 Global Hypertension Medications Forecasted Market Size by Type (2024-2034)
5 Hypertension Medications Breakdown Data by Application
5.1 Global Hypertension Medications Historic Market Size by Application (2024-2024)
5.2 Global Hypertension Medications Forecasted Market Size by Application (2024-2034)
6 North America
6.1 North America Hypertension Medications Market Size (2024-2034)
6.2 North America Hypertension Medications Market Growth Rate by Country: 2024 VS 2022 VS 2034
6.3 North America Hypertension Medications Market Size by Country (2024-2024)
6.4 North America Hypertension Medications Market Size by Country (2024-2034)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Hypertension Medications Market Size (2024-2034)
7.2 Europe Hypertension Medications Market Growth Rate by Country: 2024 VS 2022 VS 2034
7.3 Europe Hypertension Medications Market Size by Country (2024-2024)
7.4 Europe Hypertension Medications Market Size by Country (2024-2034)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Hypertension Medications Market Size (2024-2034)
8.2 Asia-Pacific Hypertension Medications Market Growth Rate by Region: 2024 VS 2022 VS 2034
8.3 Asia-Pacific Hypertension Medications Market Size by Region (2024-2024)
8.4 Asia-Pacific Hypertension Medications Market Size by Region (2024-2034)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Hypertension Medications Market Size (2024-2034)
9.2 Latin America Hypertension Medications Market Growth Rate by Country: 2024 VS 2022 VS 2034
9.3 Latin America Hypertension Medications Market Size by Country (2024-2024)
9.4 Latin America Hypertension Medications Market Size by Country (2024-2034)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hypertension Medications Market Size (2024-2034)
10.2 Middle East & Africa Hypertension Medications Market Growth Rate by Country: 2024 VS 2022 VS 2034
10.3 Middle East & Africa Hypertension Medications Market Size by Country (2024-2024)
10.4 Middle East & Africa Hypertension Medications Market Size by Country (2024-2034)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Hypertension Medications Introduction
11.1.4 Pfizer Revenue in Hypertension Medications Business (2024-2024)
11.1.5 Pfizer Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Hypertension Medications Introduction
11.2.4 Novartis Revenue in Hypertension Medications Business (2024-2024)
11.2.5 Novartis Recent Development
11.3 AstraZeneca
11.3.1 AstraZeneca Company Detail
11.3.2 AstraZeneca Business Overview
11.3.3 AstraZeneca Hypertension Medications Introduction
11.3.4 AstraZeneca Revenue in Hypertension Medications Business (2024-2024)
11.3.5 AstraZeneca Recent Development
11.4 Bayer
11.4.1 Bayer Company Detail
11.4.2 Bayer Business Overview
11.4.3 Bayer Hypertension Medications Introduction
11.4.4 Bayer Revenue in Hypertension Medications Business (2024-2024)
11.4.5 Bayer Recent Development
11.5 Sanofi
11.5.1 Sanofi Company Detail
11.5.2 Sanofi Business Overview
11.5.3 Sanofi Hypertension Medications Introduction
11.5.4 Sanofi Revenue in Hypertension Medications Business (2024-2024)
11.5.5 Sanofi Recent Development
11.6 Boehringer Ingelheim
11.6.1 Boehringer Ingelheim Company Detail
11.6.2 Boehringer Ingelheim Business Overview
11.6.3 Boehringer Ingelheim Hypertension Medications Introduction
11.6.4 Boehringer Ingelheim Revenue in Hypertension Medications Business (2024-2024)
11.6.5 Boehringer Ingelheim Recent Development
11.7 Merck
11.7.1 Merck Company Detail
11.7.2 Merck Business Overview
11.7.3 Merck Hypertension Medications Introduction
11.7.4 Merck Revenue in Hypertension Medications Business (2024-2024)
11.7.5 Merck Recent Development
11.8 Lupin Pharmaceuticals
11.8.1 Lupin Pharmaceuticals Company Detail
11.8.2 Lupin Pharmaceuticals Business Overview
11.8.3 Lupin Pharmaceuticals Hypertension Medications Introduction
11.8.4 Lupin Pharmaceuticals Revenue in Hypertension Medications Business (2024-2024)
11.8.5 Lupin Pharmaceuticals Recent Development
11.9 Huahai Pharmaceutical
11.9.1 Huahai Pharmaceutical Company Detail
11.9.2 Huahai Pharmaceutical Business Overview
11.9.3 Huahai Pharmaceutical Hypertension Medications Introduction
11.9.4 Huahai Pharmaceutical Revenue in Hypertension Medications Business (2024-2024)
11.9.5 Huahai Pharmaceutical Recent Development
11.10 Jiangsu Jibeier Pharmaceutical
11.10.1 Jiangsu Jibeier Pharmaceutical Company Detail
11.10.2 Jiangsu Jibeier Pharmaceutical Business Overview
11.10.3 Jiangsu Jibeier Pharmaceutical Hypertension Medications Introduction
11.10.4 Jiangsu Jibeier Pharmaceutical Revenue in Hypertension Medications Business (2024-2024)
11.10.5 Jiangsu Jibeier Pharmaceutical Recent Development
11.11 Tianjin Pharmaceutical Da Ren Tang Group
11.11.1 Tianjin Pharmaceutical Da Ren Tang Group Company Detail
11.11.2 Tianjin Pharmaceutical Da Ren Tang Group Business Overview
11.11.3 Tianjin Pharmaceutical Da Ren Tang Group Hypertension Medications Introduction
11.11.4 Tianjin Pharmaceutical Da Ren Tang Group Revenue in Hypertension Medications Business (2024-2024)
11.11.5 Tianjin Pharmaceutical Da Ren Tang Group Recent Development
11.12 Chengdu Easton Biopharmaceuticals
11.12.1 Chengdu Easton Biopharmaceuticals Company Detail
11.12.2 Chengdu Easton Biopharmaceuticals Business Overview
11.12.3 Chengdu Easton Biopharmaceuticals Hypertension Medications Introduction
11.12.4 Chengdu Easton Biopharmaceuticals Revenue in Hypertension Medications Business (2024-2024)
11.12.5 Chengdu Easton Biopharmaceuticals Recent Development
11.13 Qingdao Huanghai Pharmaceutical
11.13.1 Qingdao Huanghai Pharmaceutical Company Detail
11.13.2 Qingdao Huanghai Pharmaceutical Business Overview
11.13.3 Qingdao Huanghai Pharmaceutical Hypertension Medications Introduction
11.13.4 Qingdao Huanghai Pharmaceutical Revenue in Hypertension Medications Business (2024-2024)
11.13.5 Qingdao Huanghai Pharmaceutical Recent Development
11.14 CR Double-Crane
11.14.1 CR Double-Crane Company Detail
11.14.2 CR Double-Crane Business Overview
11.14.3 CR Double-Crane Hypertension Medications Introduction
11.14.4 CR Double-Crane Revenue in Hypertension Medications Business (2024-2024)
11.14.5 CR Double-Crane Recent Development
11.15 Shanghai Shyndec Pharmaceutical
11.15.1 Shanghai Shyndec Pharmaceutical Company Detail
11.15.2 Shanghai Shyndec Pharmaceutical Business Overview
11.15.3 Shanghai Shyndec Pharmaceutical Hypertension Medications Introduction
11.15.4 Shanghai Shyndec Pharmaceutical Revenue in Hypertension Medications Business (2024-2024)
11.15.5 Shanghai Shyndec Pharmaceutical Recent Development
11.16 CSPC Pharmaceutical Group
11.16.1 CSPC Pharmaceutical Group Company Detail
11.16.2 CSPC Pharmaceutical Group Business Overview
11.16.3 CSPC Pharmaceutical Group Hypertension Medications Introduction
11.16.4 CSPC Pharmaceutical Group Revenue in Hypertension Medications Business (2024-2024)
11.16.5 CSPC Pharmaceutical Group Recent Development
11.17 Jiangsu Hengrui Medicine
11.17.1 Jiangsu Hengrui Medicine Company Detail
11.17.2 Jiangsu Hengrui Medicine Business Overview
11.17.3 Jiangsu Hengrui Medicine Hypertension Medications Introduction
11.17.4 Jiangsu Hengrui Medicine Revenue in Hypertension Medications Business (2024-2024)
11.17.5 Jiangsu Hengrui Medicine Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Hypertension Medications Market Size Growth Rate by Type (US$ Million): 2024 VS 2022 VS 2034
Table 2. Key Players of Calcium Channel Blockers
Table 3. Key Players of ACE Inhibitors
Table 4. Key Players of Angiotensin II Receptor Blockers
Table 5. Key Players of Beta Blockers
Table 6. Key Players of Compound Drugs
Table 7. Key Players of Diuretics
Table 8. Key Players of Others
Table 9. Global Hypertension Medications Market Size Growth by Application (US$ Million): 2024 VS 2022 VS 2034
Table 10. Global Hypertension Medications Market Size by Region (US$ Million): 2024 VS 2022 VS 2034
Table 11. Global Hypertension Medications Market Size by Region (2024-2024) & (US$ Million)
Table 12. Global Hypertension Medications Market Share by Region (2024-2024)
Table 13. Global Hypertension Medications Forecasted Market Size by Region (2024-2034) & (US$ Million)
Table 14. Global Hypertension Medications Market Share by Region (2024-2034)
Table 15. Hypertension Medications Market Trends
Table 16. Hypertension Medications Market Drivers
Table 17. Hypertension Medications Market Challenges
Table 18. Hypertension Medications Market Restraints
Table 19. Global Hypertension Medications Revenue by Players (2024-2024) & (US$ Million)
Table 20. Global Hypertension Medications Market Share by Players (2024-2024)
Table 21. Global Top Hypertension Medications Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hypertension Medications as of 2022)
Table 22. Ranking of Global Top Hypertension Medications Companies by Revenue (US$ Million) in 2022
Table 23. Global 5 Largest Players Market Share by Hypertension Medications Revenue (CR5 and HHI) & (2024-2024)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Hypertension Medications Product Solution and Service
Table 26. Date of Enter into Hypertension Medications Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Hypertension Medications Market Size by Type (2024-2024) & (US$ Million)
Table 29. Global Hypertension Medications Revenue Market Share by Type (2024-2024)
Table 30. Global Hypertension Medications Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 31. Global Hypertension Medications Revenue Market Share by Type (2024-2034)
Table 32. Global Hypertension Medications Market Size by Application (2024-2024) & (US$ Million)
Table 33. Global Hypertension Medications Revenue Market Share by Application (2024-2024)
Table 34. Global Hypertension Medications Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 35. Global Hypertension Medications Revenue Market Share by Application (2024-2034)
Table 36. North America Hypertension Medications Market Size Growth Rate by Country (US$ Million): 2024 VS 2022 VS 2034
Table 37. North America Hypertension Medications Market Size by Country (2024-2024) & (US$ Million)
Table 38. North America Hypertension Medications Market Size by Country (2024-2034) & (US$ Million)
Table 39. Europe Hypertension Medications Market Size Growth Rate by Country (US$ Million): 2024 VS 2022 VS 2034
Table 40. Europe Hypertension Medications Market Size by Country (2024-2024) & (US$ Million)
Table 41. Europe Hypertension Medications Market Size by Country (2024-2034) & (US$ Million)
Table 42. Asia-Pacific Hypertension Medications Market Size Growth Rate by Region (US$ Million): 2024 VS 2022 VS 2034
Table 43. Asia-Pacific Hypertension Medications Market Size by Region (2024-2024) & (US$ Million)
Table 44. Asia-Pacific Hypertension Medications Market Size by Region (2024-2034) & (US$ Million)
Table 45. Latin America Hypertension Medications Market Size Growth Rate by Country (US$ Million): 2024 VS 2022 VS 2034
Table 46. Latin America Hypertension Medications Market Size by Country (2024-2024) & (US$ Million)
Table 47. Latin America Hypertension Medications Market Size by Country (2024-2034) & (US$ Million)
Table 48. Middle East & Africa Hypertension Medications Market Size Growth Rate by Country (US$ Million): 2024 VS 2022 VS 2034
Table 49. Middle East & Africa Hypertension Medications Market Size by Country (2024-2024) & (US$ Million)
Table 50. Middle East & Africa Hypertension Medications Market Size by Country (2024-2034) & (US$ Million)
Table 51. Pfizer Company Detail
Table 52. Pfizer Business Overview
Table 53. Pfizer Hypertension Medications Product
Table 54. Pfizer Revenue in Hypertension Medications Business (2024-2024) & (US$ Million)
Table 55. Pfizer Recent Development
Table 56. Novartis Company Detail
Table 57. Novartis Business Overview
Table 58. Novartis Hypertension Medications Product
Table 59. Novartis Revenue in Hypertension Medications Business (2024-2024) & (US$ Million)
Table 60. Novartis Recent Development
Table 61. AstraZeneca Company Detail
Table 62. AstraZeneca Business Overview
Table 63. AstraZeneca Hypertension Medications Product
Table 64. AstraZeneca Revenue in Hypertension Medications Business (2024-2024) & (US$ Million)
Table 65. AstraZeneca Recent Development
Table 66. Bayer Company Detail
Table 67. Bayer Business Overview
Table 68. Bayer Hypertension Medications Product
Table 69. Bayer Revenue in Hypertension Medications Business (2024-2024) & (US$ Million)
Table 70. Bayer Recent Development
Table 71. Sanofi Company Detail
Table 72. Sanofi Business Overview
Table 73. Sanofi Hypertension Medications Product
Table 74. Sanofi Revenue in Hypertension Medications Business (2024-2024) & (US$ Million)
Table 75. Sanofi Recent Development
Table 76. Boehringer Ingelheim Company Detail
Table 77. Boehringer Ingelheim Business Overview
Table 78. Boehringer Ingelheim Hypertension Medications Product
Table 79. Boehringer Ingelheim Revenue in Hypertension Medications Business (2024-2024) & (US$ Million)
Table 80. Boehringer Ingelheim Recent Development
Table 81. Merck Company Detail
Table 82. Merck Business Overview
Table 83. Merck Hypertension Medications Product
Table 84. Merck Revenue in Hypertension Medications Business (2024-2024) & (US$ Million)
Table 85. Merck Recent Development
Table 86. Lupin Pharmaceuticals Company Detail
Table 87. Lupin Pharmaceuticals Business Overview
Table 88. Lupin Pharmaceuticals Hypertension Medications Product
Table 89. Lupin Pharmaceuticals Revenue in Hypertension Medications Business (2024-2024) & (US$ Million)
Table 90. Lupin Pharmaceuticals Recent Development
Table 91. Huahai Pharmaceutical Company Detail
Table 92. Huahai Pharmaceutical Business Overview
Table 93. Huahai Pharmaceutical Hypertension Medications Product
Table 94. Huahai Pharmaceutical Revenue in Hypertension Medications Business (2024-2024) & (US$ Million)
Table 95. Huahai Pharmaceutical Recent Development
Table 96. Jiangsu Jibeier Pharmaceutical Company Detail
Table 97. Jiangsu Jibeier Pharmaceutical Business Overview
Table 98. Jiangsu Jibeier Pharmaceutical Hypertension Medications Product
Table 99. Jiangsu Jibeier Pharmaceutical Revenue in Hypertension Medications Business (2024-2024) & (US$ Million)
Table 100. Jiangsu Jibeier Pharmaceutical Recent Development
Table 101. Tianjin Pharmaceutical Da Ren Tang Group Company Detail
Table 102. Tianjin Pharmaceutical Da Ren Tang Group Business Overview
Table 103. Tianjin Pharmaceutical Da Ren Tang Group Hypertension Medications Product
Table 104. Tianjin Pharmaceutical Da Ren Tang Group Revenue in Hypertension Medications Business (2024-2024) & (US$ Million)
Table 105. Tianjin Pharmaceutical Da Ren Tang Group Recent Development
Table 106. Chengdu Easton Biopharmaceuticals Company Detail
Table 107. Chengdu Easton Biopharmaceuticals Business Overview
Table 108. Chengdu Easton Biopharmaceuticals Hypertension Medications Product
Table 109. Chengdu Easton Biopharmaceuticals Revenue in Hypertension Medications Business (2024-2024) & (US$ Million)
Table 110. Chengdu Easton Biopharmaceuticals Recent Development
Table 111. Qingdao Huanghai Pharmaceutical Company Detail
Table 112. Qingdao Huanghai Pharmaceutical Business Overview
Table 113. Qingdao Huanghai Pharmaceutical Hypertension Medications Product
Table 114. Qingdao Huanghai Pharmaceutical Revenue in Hypertension Medications Business (2024-2024) & (US$ Million)
Table 115. Qingdao Huanghai Pharmaceutical Recent Development
Table 116. CR Double-Crane Company Detail
Table 117. CR Double-Crane Business Overview
Table 118. CR Double-Crane Hypertension Medications Product
Table 119. CR Double-Crane Revenue in Hypertension Medications Business (2024-2024) & (US$ Million)
Table 120. CR Double-Crane Recent Development
Table 121. Shanghai Shyndec Pharmaceutical Company Detail
Table 122. Shanghai Shyndec Pharmaceutical Business Overview
Table 123. Shanghai Shyndec Pharmaceutical Hypertension Medications Product
Table 124. Shanghai Shyndec Pharmaceutical Revenue in Hypertension Medications Business (2024-2024) & (US$ Million)
Table 125. Shanghai Shyndec Pharmaceutical Recent Development
Table 126. CSPC Pharmaceutical Group Company Detail
Table 127. CSPC Pharmaceutical Group Business Overview
Table 128. CSPC Pharmaceutical Group Hypertension Medications Product
Table 129. CSPC Pharmaceutical Group Revenue in Hypertension Medications Business (2024-2024) & (US$ Million)
Table 130. CSPC Pharmaceutical Group Recent Development
Table 131. Jiangsu Hengrui Medicine Company Detail
Table 132. Jiangsu Hengrui Medicine Business Overview
Table 133. Jiangsu Hengrui Medicine Hypertension Medications Product
Table 134. Jiangsu Hengrui Medicine Revenue in Hypertension Medications Business (2024-2024) & (US$ Million)
Table 135. Jiangsu Hengrui Medicine Recent Development
Table 136. Research Programs/Design for This Report
Table 137. Key Data Information from Secondary Sources
Table 138. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Hypertension Medications Market Size Comparison by Type (2024-2034) & (US$ Million)
Figure 2. Global Hypertension Medications Market Share by Type: 2022 VS 2034
Figure 3. Calcium Channel Blockers Features
Figure 4. ACE Inhibitors Features
Figure 5. Angiotensin II Receptor Blockers Features
Figure 6. Beta Blockers Features
Figure 7. Compound Drugs Features
Figure 8. Diuretics Features
Figure 9. Others Features
Figure 10. Global Hypertension Medications Market Size Comparison by Application (2024-2034) & (US$ Million)
Figure 11. Global Hypertension Medications Market Share by Application: 2022 VS 2034
Figure 12. Hospital Case Studies
Figure 13. Clinic Case Studies
Figure 14. Others Case Studies
Figure 15. Hypertension Medications Report Years Considered
Figure 16. Global Hypertension Medications Market Size (US$ Million), Year-over-Year: 2024-2034
Figure 17. Global Hypertension Medications Market Size, (US$ Million), 2024 VS 2022 VS 2034
Figure 18. Global Hypertension Medications Market Share by Region: 2022 VS 2034
Figure 19. Global Hypertension Medications Market Share by Players in 2022
Figure 20. Global Top Hypertension Medications Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hypertension Medications as of 2022)
Figure 21. The Top 10 and 5 Players Market Share by Hypertension Medications Revenue in 2022
Figure 22. North America Hypertension Medications Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 23. North America Hypertension Medications Market Share by Country (2024-2034)
Figure 24. United States Hypertension Medications Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 25. Canada Hypertension Medications Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 26. Europe Hypertension Medications Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 27. Europe Hypertension Medications Market Share by Country (2024-2034)
Figure 28. Germany Hypertension Medications Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 29. France Hypertension Medications Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 30. U.K. Hypertension Medications Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 31. Italy Hypertension Medications Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 32. Russia Hypertension Medications Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 33. Nordic Countries Hypertension Medications Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 34. Asia-Pacific Hypertension Medications Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 35. Asia-Pacific Hypertension Medications Market Share by Region (2024-2034)
Figure 36. China Hypertension Medications Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 37. Japan Hypertension Medications Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 38. South Korea Hypertension Medications Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 39. Southeast Asia Hypertension Medications Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 40. India Hypertension Medications Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 41. Australia Hypertension Medications Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 42. Latin America Hypertension Medications Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 43. Latin America Hypertension Medications Market Share by Country (2024-2034)
Figure 44. Mexico Hypertension Medications Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 45. Brazil Hypertension Medications Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 46. Middle East & Africa Hypertension Medications Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 47. Middle East & Africa Hypertension Medications Market Share by Country (2024-2034)
Figure 48. Turkey Hypertension Medications Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 49. Saudi Arabia Hypertension Medications Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 50. Pfizer Revenue Growth Rate in Hypertension Medications Business (2024-2024)
Figure 51. Novartis Revenue Growth Rate in Hypertension Medications Business (2024-2024)
Figure 52. AstraZeneca Revenue Growth Rate in Hypertension Medications Business (2024-2024)
Figure 53. Bayer Revenue Growth Rate in Hypertension Medications Business (2024-2024)
Figure 54. Sanofi Revenue Growth Rate in Hypertension Medications Business (2024-2024)
Figure 55. Boehringer Ingelheim Revenue Growth Rate in Hypertension Medications Business (2024-2024)
Figure 56. Merck Revenue Growth Rate in Hypertension Medications Business (2024-2024)
Figure 57. Lupin Pharmaceuticals Revenue Growth Rate in Hypertension Medications Business (2024-2024)
Figure 58. Huahai Pharmaceutical Revenue Growth Rate in Hypertension Medications Business (2024-2024)
Figure 59. Jiangsu Jibeier Pharmaceutical Revenue Growth Rate in Hypertension Medications Business (2024-2024)
Figure 60. Tianjin Pharmaceutical Da Ren Tang Group Revenue Growth Rate in Hypertension Medications Business (2024-2024)
Figure 61. Chengdu Easton Biopharmaceuticals Revenue Growth Rate in Hypertension Medications Business (2024-2024)
Figure 62. Qingdao Huanghai Pharmaceutical Revenue Growth Rate in Hypertension Medications Business (2024-2024)
Figure 63. CR Double-Crane Revenue Growth Rate in Hypertension Medications Business (2024-2024)
Figure 64. Shanghai Shyndec Pharmaceutical Revenue Growth Rate in Hypertension Medications Business (2024-2024)
Figure 65. CSPC Pharmaceutical Group Revenue Growth Rate in Hypertension Medications Business (2024-2024)
Figure 66. Jiangsu Hengrui Medicine Revenue Growth Rate in Hypertension Medications Business (2024-2024)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed